ArticleJournal of breast cancer2015
Malignant Adenomyoepithelioma of the Breast and Responsiveness to Eribulin.
Article in Journal of breast cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 32 citations in OpenAlex.
- Malignant breast adenomyoepithelioma with diagnostic discordance: a case report and literature review.Frontiers in oncology · 2026Article
- Malignant adenomyoepithelioma of the breast with axillary metastasis: a case report in a patient undergoingFrontiers in oncology · 2026Article
- Triple-Negative Breast Cancer Coexisting with Adenomyoepithelioma: A Case Report.Journal of the Korean Society of Radiology · 2026Article
- Targeting malignant adenomyoepithelioma of the breast: clinical insights on multimodal therapy and disease-free survival.Discover oncology · 2025Article
- Malignant adenomyoepithelioma of the breast with axillary lymph node metastasis: a case report and review of the literature.Frontiers in oncology · 2025Article
- Can Epithelial-Myoepithelial Carcinoma of the Breast Benefit from TROP2 Antibody-Drug Conjugate?OncoTargets and therapy · 2025Article
- Article
- Concurrence of Adenomyoepithelioma of the Breast and Gastrointestinal Stromal Tumor of the Stomach: A Case Report and Review of the Literature.Medical sciences (Basel, Switzerland) · 2023Review
- Case report and literature review: Malignant adenomyoepithelioma after breast augmentation.Frontiers in surgery · 2022Article
- Malignant adenomyoepithelioma of the breast: Two case reports and review of the literature.World journal of clinical cases · 2021Article
- Adenomyoepithelioma of the breast with malignant transformation and repeated local recurrence: A case report.World journal of clinical cases · 2021Article
- Adenomyoepithelial tumors of the breast: molecular underpinnings of a rare entity.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2020Article
- Malignant adenomyoepithelioma of the breast.Surgical case reports · 2020Article
- Metaplastic breast carcinoma composed of epithelial-myoepithelial carcinoma and squamous cell carcinoma: A case report.Medicine · 2018Article
- Article
- Adenomyoepithelioma of the breast with late pulmonary metastases - case report and review of the literature.Journal of cardiothoracic surgery · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adenomyoepithelioma (AME) of the breast is an uncommon tumor characterized by its dual differentiation into luminal cells and myoepithelial cells. In most cases these tumors have a benign clinical course, but distant metastases have been reported. We present the case of a 51-year-old woman diagnosed with malignant AME. The patient underwent a right modified radical mastectomy, and pathological examination confirmed the diagnosis of malignant AME. Ten months after the operation, multiple hepatic, pleural, and abdominal wall metastases were detected. A number of palliative chemotherapeutic agents were tried, including anthracycline and taxanes. However, the disease continued to progress, and superior vena cava syndrome developed as a result of direct tumor invasion. The patient received salvage eribulin monotherapy. After two cycles of this treatment, her clinical symptoms were ameliorated, and a computed tomography scan showed a partial response. Eribulin chemotherapy was thus effective in treating malignant AME in this case.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.